Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (the "Company") on September 26, 2016, for the month of September 2016. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding regulatory compliance and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the Company's commitment to report in accordance with the U.S. Securities Exchange Act of 1934, as amended. This action aligns with Section E3 and Chapter F of the Israeli Securities Law, 5728-1968. The reporting requirement was approved by Series 1 option holders, shareholders, and holders of American Depositary Shares on September 4, 2016, September 18, 2016, and September 25, 2016, respectively.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the procedural approval of U.S. reporting standards.
Key Facts for Investor Verification
- The Company is transitioning its reporting framework to comply with the U.S. Securities Exchange Act of 1934.
- Approval for this reporting change was obtained from Series 1 option holders, shareholders, and ADS holders in September 2016.
- No financial performance data is included in this specific filing.
- The filing was signed by Dr. Shai Yarkoni, Chief Executive Officer, on September 26, 2016.